Literature DB >> 34117085

Single-Cell Analysis of the Pan-Cancer Immune Microenvironment and scTIME Portal.

Fang Hong1, Qianqian Meng1, Weiyu Zhang1, Ruiqin Zheng1, Xiaoyun Li1, Tao Cheng2, Deqing Hu3, Xin Gao2.   

Abstract

Single-cell sequencing opens a new era for the investigation of tumor immune microenvironments (TIME). However, at single-cell resolution, a pan-cancer analysis that addresses the identity and diversity of TIMEs is lacking. Here, we first built a pan-cancer single-cell reference of TIMEs with refined subcell types and recognized new cell type-specific transcription factors. We then presented a pan-cancer view of the common features of the TIME and compared the variation of each immune cell type across patients and tumor types in the aspects of abundance, cell states, and cell communications. We found that the abundance and the cell states of dysfunctional T cells were most variable, whereas those of regulatory T cells were relatively stable. A subset of tumor-associated macrophages (TAM), PLTP + C1QC + TAMs, may regulate the abundance of dysfunctional T cells through cytokine/chemokine signaling. The ligand-receptor communication network of TIMEs was tumor-type specific and dominated by the tumor-enriched immune cells. We additionally developed the single-cell TIME (scTIME) portal (http://scTIME.sklehabc.com) with the scTIME-specific analysis modules and a unified cell annotation. In addition to the immune cell compositions and correlation analysis using refined cell type classifications, the portal also provides cell-cell interaction and cell type-specific gene signature analysis. Our single-cell pan-cancer analysis and scTIME portal will provide more insights into the features of TIMEs, as well as the molecular and cellular mechanisms underlying immunotherapies. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2021        PMID: 34117085     DOI: 10.1158/2326-6066.CIR-20-1026

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  6 in total

1.  CD93 is Associated with Glioma-related Malignant Processes and Immunosuppressive Cell Infiltration as an Inspiring Biomarker of Survivance.

Authors:  Kaiming Ma; Suhua Chen; Xin Chen; Xiaofang Zhao; Jun Yang
Journal:  J Mol Neurosci       Date:  2022-08-25       Impact factor: 2.866

2.  Spatiotemporal co-dependency between macrophages and exhausted CD8+ T cells in cancer.

Authors:  Kelly Kersten; Kenneth H Hu; Alexis J Combes; Bushra Samad; Tory Harwin; Arja Ray; Arjun Arkal Rao; En Cai; Kyle Marchuk; Jordan Artichoker; Tristan Courau; Quanming Shi; Julia Belk; Ansuman T Satpathy; Matthew F Krummel
Journal:  Cancer Cell       Date:  2022-05-26       Impact factor: 38.585

3.  Genetic Cross-Talk between Oral Squamous Cell Carcinoma and Type 2 Diabetes: The Potential Role of Immunity.

Authors:  Yunjian Fan; Jie Zhang; Jiayu Shi; Lin Chen; Jiazhen Long; Shuqi Zhang; Shuguang Liu
Journal:  Dis Markers       Date:  2022-05-19       Impact factor: 3.464

4.  Single-cell landscape reveals active cell subtypes and their interaction in the tumor microenvironment of gastric cancer.

Authors:  Yumin Li; Xueda Hu; Ruichai Lin; Guangyu Zhou; Lulu Zhao; Dongbing Zhao; Yawei Zhang; Wenbin Li; Yueming Zhang; Peiqin Ma; Hu Ren; Xinhui Liao; Penghui Niu; Tongbo Wang; Xiaojie Zhang; Wanqing Wang; Ranran Gao; Qibin Li; George Church; Jie He; Yingtai Chen
Journal:  Theranostics       Date:  2022-05-09       Impact factor: 11.600

5.  Mapk14 is a Prognostic Biomarker and Correlates with the Clinicopathological Features and Immune Infiltration of Colorectal Cancer.

Authors:  Dan Wang; Li Peng; Li Hua; Jiaxiang Li; Yifei Liu; Yanhong Zhou
Journal:  Front Cell Dev Biol       Date:  2022-01-24

6.  Prediction of prognosis, immunogenicity and efficacy of immunotherapy based on glutamine metabolism in lung adenocarcinoma.

Authors:  Jichang Liu; Hongchang Shen; Wenchao Gu; Haotian Zheng; Yadong Wang; Guoyuan Ma; Jiajun Du
Journal:  Front Immunol       Date:  2022-08-11       Impact factor: 8.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.